Blood typing tests and reagents
AssigneeOrtho Diagnostics, Inc.
InventorsHenry A. Graham, Jr., David J. Olekna, Johnna B. Hawk, Diane B. Kebles
Life of this patent
Estimating the term…
Abstract
Methods and reagents for determination of Rh.sub.o (D), C, c, E, e, and K antigens in human blood. The reagents are low-protein compositions containing reduced and S-alkylated IgG antibody to the selected antigen maintained at a pH of between about 7.5 and 8.3. These reagents meet or exceed FDA standards for potency and specificity of the respective antisera.
Claims13
A method for rapidly determining the presence or absence on the red blood cells of a given individual of an antigen selected from C, c, E, e, and K which comprises the steps of:
- (a) obtaining a sample of red blood cells to be tested;
- (b) adding to and mixing with said sample an antibody reagent to form a mixture;
- and
- (c) without substantial incubation observing said mixture to determine whether agglutination does or does not occur;
- wherein said antibody reagent comprises reduced and S-alkylated IgG antibody to the selected antigen which in the case of anti-C has an average titer of at least 5 with dCce or DCcEe cells;
- in the case of anti-c has an average titer of at least 16 with dCce cells;
- in the case of anti-E has an average titer of at least 8 with dcEe cells;
- in the case of anti-e has an average titer of at least 2 with dcEe cells;
- and in the case of anti-K has an average titer of at least 8 for cells which are heterozygous for the K antigen.
A slide test method for rapidly determining the presence or absence on the red blood cells of a given individual of an antigen selected from C, c, E, and e, which comprises the steps of:
- (a) obtaining a sample of red blood cells to be tested;
- (b) on a test slide, adding to and mixing with said sample an antibody reagent to form a mixture;
- and
- (c) without incubation observing said mixture to determine whether agglutination does or does not occur;
- wherein said antibody reagent comprises reduced and S-alkylated IgG antibody to the selected antigen which in the case of anti-C has an average titer of at least 5 with dCce or DCcEe cells;
- in the case of anti-c has an average titer of at least 16 with dCce cells;
- in the case of anti-E has an average titer of at least 8 with dcEe cells;
- and in the case of anti-e has an average titer of at least 2 with dcEe cells.
An antibody reagent useful for rapidly determining the presence or absence on red blood cells of an antigen selected from the group consisting of C, c, E, e, and K which antibody reagent, in the case of anti-C has an average titer of at least 5 with dCce or DCcEe cells;
- in the case of anti-c has an average titer of at least 16 with dCce cells;
- in the case of anti-E has an average titer of at least 8 with dcEe cells;
- in the case of anti-e has an average titer of at least 2 with dcEe cells;
- and in the case of anti-K has an average titer of at least 8 for cells which are heterozygous for the K antigen which comprises reduced, S-alkylated, IgG antibody to the selected antigen maintained at a pH of between about 7.5 and 8.3 by an effective buffering amount of a compatible buffer in a medium containing from about 6-10% by weight total protein.
A method for preparing an antibody reagent useful for rapidly determining the presence or absence on red blood cells of an antigen selected from C, c, E, e, and K, which antibody reagent in the case of anti-C has an average titer of at least 5 with dCce or DCcEe cells;
- in the case of anti-c has an average titer of at least 16 with dCce cells;
- in the case of anti-E has an average titer of at least 8 with dcEe cells;
- in the case of anti-e has an average titer of at least 2 with dcEe cells;
- and in the case of anti-K has an average titer of at least 8 for cells which are heterozygous for the K antigen which comprises the steps of:
- (a) obtaining a substantially lipid-free human antiserum containing IgG antibody to the selected antigen;
- (b) adjusting the pH of said antiserum to about 8.6 by addition of an effective buffering amount of a compatible buffer;
- (c) reducing said buffered antiserum with a reducing agent;
- (d) S-alkylating said reduced buffered antiserum with an S-alkylating agent;
- (e) dialyzing said S-alkylated reduced antiserum at a pH between 7.5 and 8.3;
- and
- (f) adjusting the total protein concentration to about 6-10% by weight by addition of a nonspecific protein.
Dependencies are inferred from the claim text.